The Opioid Epidemic in Philadelphia
Implementation of the Mayor’s Task Force Recommendations

Status Report to the

Mayor’s Drug and Alcohol Executive Commission

December 13, 2017
# Table of Contents

I. Introduction 2

II. Graphs of Core Task Force Metrics 3

III. Progress on the Task Force’s Recommendations
   a. Prevention and Education 10
   b. Treatment 11
   c. Overdose Prevention 13
   d. Involvement of the Criminal Justice System 14

IV. Data 14

V. Succeeding in Recovery 15

VI. DBHIDS Advancing the Substance Use Disorder Treatment Continuum Fact Sheet and DBHDIS In-Network Adult Community MAT Provider List
Introduction

On May 19, 2017, Mayor James Kenney’s Task Force to Combat the Opioid Epidemic in Philadelphia released its final report and recommendations. The 18 recommendations – organized by Prevention and Education, Treatment, Overdose Prevention and Criminal Justice – provide actionable, evidence-based steps the City and its partners can take to reduce the harmful effects of opioids in our community.

The importance of these recommendations cannot be overstated. This epidemic continues to claim Philadelphians’ lives every day—907 individuals died of an overdose in 2016 and we project that as many as 1,200 may die in 2017.1 Thousands of Philadelphia residents had non-fatal overdoses, while an estimated 469,000 people used a prescription opioid in the last year.2 Addressing the crisis is one of the City’s top priorities.

The Task Force resulted in new targeted efforts and opportunities, and implementation of the recommendations is underway across the city. Since the last status report, progress has been made on all 18 recommendations. Graphs of the Task Force’s Key Metrics can be found on the following page.

This report is the second of quarterly reports to the Mayor’s Drug and Alcohol Executive Commission and summarizes the progress made towards full implementation of the recommendations. Previous quarterly reports can be found at: http://www.phila.gov/opioids

---

1 Medical Examiner’s Office, Philadelphia Department of Public Health.
Graphs of Core Task Force Metrics from the Opioid Misuse and Overdose Report, Philadelphia, PA (last updated December, 2017)

Additional data can be found on the Health Information Portal’s Opioid Surveillance Page: [https://hip.phila.gov/DataReports/Opioid](https://hip.phila.gov/DataReports/Opioid)
Drug Treatment Metrics

Total DBHIDS In-Network MAT Program Capacity (any medication) = 8,707 slots as of 11/30/17.
In 2016, DBHIDS increased in-network capacity of buprenorphine treatment by more than 1,000 slots.

Philadelphia DBHIDS In-Network Adult Community Medication-Assisted Treatment Capacity, as of 11/30/2017

Total DBHIDS Community MAT Program Capacity (any medication) = 8,707 slots.
2,219 MAT slots are available as of 11/30/2107.
Naloxone – doses distributed

Since July 1, 2017, the City has distributed **19,461 doses of naloxone** to law enforcement agencies and other organizations:

- **Providers and Community Organizations**: 16,553 doses
- **Criminal justice organizations**: 2,476 doses
- **Philadelphia Police Department and SEPTA Police**: 432 doses

Naloxone – doses administered by first responders

![Graph showing naloxone doses administered by first responders from 2014 to Q3 2017.](image-url)
Rate of Drug Related ED Visits
per 1,000 Visits by Year, 2007-2017

*Data for 2017 is incomplete and subject to change*
**Strategy 1: Prevention and Education**

Despite the magnitude of the opioid epidemic in Philadelphia, public awareness is low about the dangers of opioids and the need to recognize, intervene, and support people who may be opioid dependent. In addition, doctors and other prescribers still prescribe too many opioids. This strategy area focuses on developing recommendations to change behaviors around use of prescription opioids, including through mass media campaigns, education for doctors and other prescribers and insurance policies, as well as recommendations to increase public awareness about how to help people with opioid use disorder. Addressing stigma will be a core part of making prevention and education efforts successful, but also will ease the entire task of combatting the city’s opioid epidemic.

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Status</th>
<th>Progress Highlights</th>
</tr>
</thead>
</table>
| 2. Conduct a public education campaign about naloxone. | Planning | PDPH is developing a campaign to increase awareness about the signs and symptoms of overdose, how to obtain and use naloxone, and the Good Samaritan law. It is anticipated that the campaign will launch in early 2018. PDPH and DBHIDS continue to:  
  - Raise awareness about opioid overdoses and naloxone through public educational sessions and trainings. |
| 3. Destigmatize opioid use disorder and its treatment. | Planning / Implementing | DBHIDS is developing a page on the DBHIDS website to inform the public and other key stakeholders about the community based treatment options for Medication-Assisted Treatment (MAT) in the city, so current capacity is optimized, and individuals with opioid use disorder (OUD) are directed to evidence-based treatments. DBHIDS is planning Community Empowerment Mini-Grants to address the opioid epidemic by issuing small grants in the community. DBHIDS has a staff team visiting DBHIDS-Funded Recovery Houses to provide information on MAT to provider staff.  
DBHIDS continues to:  
  - Require all halfway houses to accept individuals on all forms of MAT and psychiatric medications to decrease discrimination.  
  - Host MAT trainings, most recently to homeless outreach and safe haven staff, and provide on-site technical assistance for providers to increase knowledge related to MAT.  
  - Encourage individuals who achieved recovery through MAT to share their recovery stories to be utilized for storytelling opportunities.  
  - Develop opportunities to host MAT information on the Evidence-based Practice and Innovation Center (EPIC) website in collaboration with the SAMHSA Addiction Technology Transfer Center. |
| 4. Improve health care professional education. | Planning / Implementing | PDPH and DBHIDS mailed opioid and benzodiazepine prescribing guidelines to 16,000 health care providers in Southeastern PA. Since the last status report, PDPH launched in November 2017 an academic detailing program, in which 1,400 health care providers across the city receive one-on-one guidance on how to prescribe judiciously. Leadership from PDPH and DBHIDS visited all of the major health systems serving adult patients in Philadelphia, and is working with them to reduce overprescribing of opioids and benzodiazepines. The City is also developing a provider dashboard for the Medicaid system to be utilized to identify and educate high volume providers of opioids. |
| 5. Establish insurance policies that support safer opioid prescribing and appropriate treatment. | Implementing | PDPH participated in a statewide discussion with insurers in Harrisburg, and is continuing to work with public and private health insurers to establish policies that support safer opioid prescribing and improve access to medication assisted treatment. Independence Blue Cross and all four Medicaid managed care organizations in Philadelphia are implementing policies to reduce overprescribing to their members. |
Strategy 2: **Treatment**

Many barriers impede access to quality treatment for substance use, including a shortage of sites that provide medication-assisted treatment, gaps in services for special populations, restrictive hours of operation, antiquated treatment modalities, requirements of clients for state-issued identification cards, housing issues, workforce limitations, and the separation of behavioral health treatment from physical health care.

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Status</th>
<th>Progress Highlights</th>
</tr>
</thead>
</table>
| 6. Increase the provision of medication-assisted treatment. | Planning / Implementing | DBHIDS has received approval from DDAP to use State Targeted Response Grant funds for MAT (specifically buprenorphine and Vivitrol) with under/uninsured individuals. DBHIDS held a focus group with Methadone Maintenance Treatment (MMT) providers exploring the barriers to offering all forms of MAT. Since the last Status Report, DBHIDS increased MAT capacity by 558 slots making total MAT capacity 8,707 slots, of which 2,219 are available. DBHIDS is planning a MAT Learning Collaborative to increase access and provision of MAT. The Center for Mental Health Policy and Services Research will meet with providers then draft policy recommendations to DBHIDS on how to best address and eliminate barriers so that adoption of MAT can be supported. DBHIDS continues to:  
- Partner with PDPH and the SAMHSA Addiction Technology Transfer Center to host Buprenorphine Waiver Trainings and other MAT Trainings. Trainings have been held with Penn and Jefferson Hospitals to increase prescriber capacity.  
- Plan for the development of a 24/7 walk-in center where individuals can receive immediate stabilization with MAT in an outpatient setting and access further treatment. This is expected to be operational in the 1st Quarter of CY18.  
- Require all newly procured addiction treatment facilities to accept MAT.  
- Plan for a specific evidence-based practice (EBP) Certification for MAT for the DBHIDS provider network, marketing the EBP nature of MAT and incentivizing program level standards. |
| 7. Expand treatment access and capacity. | Planning / Implementing | DBHIDS added a seventh program to The Journey of Hope Project which increased capacity to 128 slots. BHSI reinforced their walk-in policy under which BHSI Clinical Service Management offers in-person screening in addition to telephonic screening for under/uninsured individuals seeking access to substance use disorder (SUD) treatment. DBHIDS is initiating a mobile engagement unit through Prevention Point Philadelphia (PPP) with staff from PPP, DBHIDS, and volunteer MDs/RNs. Beginning in December 2017, staff will travel in a van to individuals displaced from Gurney Street in the Kensington/Fairhill area. DBHIDS continues to:  
- Support eight newly funded SUD Early Intervention Programs that target adolescents, families, and at-risk adults across the entire city at both provider agencies and in the community and provide individual, group, and family therapy and service linkages.  
- Require significant clinical enhancements for new procurements including increased staff qualifications, integrated psychiatric and lab services, MAT provision requirements, emphasis on linkage to next level of care, transformation from detoxification to withdrawal management, peer support, implementation of American Society of Addiction Medicine (ASAM) Criteria, ambulatory stabilization, and the expansion of Opioid Treatment Programs. The services will expand the continuum and treatment capacity including increased hospital based and residential rehabilitation capacity, increased |
halfway house beds and ambulatory stabilization programs to rapidly engage individuals in need of treatment.

| 8. Embed withdrawal management into all levels of care, with an emphasis on recovery initiation. | Planning / Implementing | DBHIDS is exploring the incorporation of withdrawal management with MAT induction into the Journey of Hope Project. DBHIDS continues to:
- Plan for the implementation of ASAM Criteria, which recognizes withdrawal management embedded in all levels of care, instead of traditional detoxification.
- Negotiate with awardees for new ambulatory stabilization programs resulting from a recently issued RFP, which aimed to expand withdrawal management into ambulatory programs. |

| 9. Implement “warm handoffs” to treatment after overdose. | Planning / Implementing | DBHIDS is launching the Recovery Overdose Survivor Engagement (ROSE) Project through PRO-ACT on December 4, 2017. Beginning in Temple Episcopal Emergency Room and Crisis Response Center (with plans to expand to Temple University Hospital), Certified Recovery Specialists (CRS) will provide warm handoff services to any individual who is at risk of or has survived an opioid overdose, with plans to expand to other emergency departments. A joint meeting with representatives from emergency departments, PDPH, and DBHIDS is being scheduled for Jan 2018. DBHIDS is also contracting with PRO-ACT to deploy CRS in the community, particularly targeting individuals who are presenting to acute medical settings such as inpatient medical and emergency department settings with other opioid related issues. The goal is to increase engagement and encourage linkage to addiction treatment. DBHIDS continues to:
- Work with the Pennsylvania State Office of Mental Health and Substance Abuse Services (OMHSAS) on the implementation of CRS as a supplemental service.
- Work collaboratively with PDPH to develop buprenorphine induction protocols in emergency departments in order to increase the likelihood that individuals will link to addiction treatment. |

| 10. Provide safe housing, recovery, and vocational supports. | Planning / Implementing | DBHIDS is projecting to increase Halfway House capacity by more than 100 slots as a result of the Specialized Alcohol and Other Drugs Services RFP. Within DBHIDS, BHSI Intensive Case Management created a new Assertive Outreach Team which provides same day case management authorization and is currently serving 147 participants with OUD, working closely with all MAT providers, the Coordinated Response to Addiction by Facilitating Treatment (CRAFT) Project, and Prevention Point Philadelphia. The team also includes a certified peer specialist working specifically with the CRAFT Project. DBHIDS continues to:
- Coordinate with HUD, OVR, and several other organizations to pilot a Homeless Job Seekers Employment Program targeting individuals with SUD.
- Work with First Step (a staffing agency) that will service individuals who are homeless and people in recovery.
- Increase capacity of Housing First by supporting 60 additional slots through Pathways to Housing targeting individuals from Kensington with OUD. |

| 11. Incentivize providers to enhance the quality of SUD screening, treatment, and workforce. | Planning | DBHIDS is working with various SUD Treatment providers to implement and sustain Prolonged Exposure and Cognitive Therapy through the Beck Community Initiative throughout their locations and levels of care. An additional intensive outpatient program will be selected via a Request for Applications. DBHIDS is finalizing a MAT credentialing protocol for outpatient providers. DBHIDS staff visited Crisis Response Centers (CRCs) to assess their knowledge of levels of care for SUD treatment. DBHIDS is planning to convene Emergency Departments, MAT providers, and Centers of Excellence to provide further education on the continuum of SUD treatment and services, create linkages for warm hand-offs and care coordination, and offer MAT as evidence- |
based OUD treatment. DBHIDS held an Addictions Provider Forum on November 30, 2017.
DBHIDS continues to:
- Enhance the capacity of the Temple Episcopal Crisis Response Center to engage, assess and treat individuals with OUD. Buprenorphine inductions and extended stabilization will be available through this expansion. This will foster the training of various health professionals in SUD, including social workers, RNs, and MDs.
- Require provision of more licensed staff to support the treatment of individuals with addiction through recent RFPs for addiction services.
- Draft new standards for assessment and develop an ASAM training plan for its network.

Strategy 3: Overdose Prevention

Not all opioid users are able and willing to begin drug treatment. Until those persons do begin treatment, actions can be taken to increase use of health and treatment services and reduce fatalities, non-fatal overdoses, and the infectious complications (HIV, hepatitis B and C, infections) of drug use.

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Status</th>
<th>Progress Highlights</th>
</tr>
</thead>
</table>
| 12. Expand naloxone availability. | Implementing | PDPH and DBHIDS were awarded a statewide grant for an additional 8,000 doses of naloxone over 2 years. Data on non-fatal and fatal are guiding the distribution of over 35,000 doses of naloxone to people at highest risk of an overdose and in high risk settings. Also in the interim, DBHIDS hosted two overdose awareness and naloxone training, training 475 people. PDPH has expanded its opioid program to include a Harm Reduction Coordinator who is offering overdose awareness and naloxone training to other city agencies and the public. PDPH and DBHIDS continue to:
  - Work with other city agencies and community organizations to implement a city-wide naloxone distribution strategy.
  - Partner with community organizations to increase naloxone availability in pharmacies in Philadelphia. |
| 13. Further explore comprehensive user engagement sites. | Implementing | The City continues to explore the issue by consulting experts and reviewing studies of user engagement facilities that allow safe injection. A City delegation visited Insite, the most well-studied facility in North America, in November 2017, and met with local leaders on the issue. |
| 14. Establish a coordinated rapid response to “outbreaks.” | Planning | PDPH and DBHIDS have begun to plan for the development a cross-departmental rapid response team. DBHIDS is partnering with PRO-ACT to make trained volunteers, family members, certified recovery specialists, and certified peer specialists available for assistance in responding to the opioid outbreaks. PDPH, DBHIDS and PPD continue to partner on establishing a rapid response protocol that involves both public health and public safety approaches. |
| 15. Address homelessness among opioid users. | Planning / Implementing | DBHIDS has received approval from DDAP to use STR Grant funds to pilot an Identification Card Acquisition Program five days per week at Prevention Point Philadelphia. The City, DBHIDS, and Project HOME are partnering to launch a full-service homeless outreach engagement center in January 2018 offering medical, behavioral health, and social services. DBHIDS continues to:
  - Create new capacity for DBHIDS Funded Recovery Houses, which will target homeless individuals with OUD leaving Gurney Street. |
• Develop the newly created bilingual homeless outreach team at Prevention Point Philadelphia targeting individuals experiencing homelessness with OUD in the Gurney Street/Fairhill area.
Strategy 4: Involvement of the Criminal Justice System

Individuals in the justice system continuum, from arrestees to sentenced prisoners, with OUD who are not participating in adequate treatment services constitute a particularly risky population. A change to a public health approach within the justice system is urgently needed, however, members of the Justice System, Law Enforcement, and First Responders subcommittee reported systemic barriers and gaps in programming, resources, and training which must be addressed in Philadelphia to enable implementation of an evidence-based public health strategy.

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Status</th>
<th>Progress Highlights</th>
</tr>
</thead>
<tbody>
<tr>
<td>16. Expand the court’s capacity for diversion to treatment.</td>
<td>Planning / Implementing</td>
<td>DBHIDS and the District Attorney’s Office continue to mutually support existing diversion programs – Accelerated Misdemeanor Program (AMP) I &amp; AMP II – and agreed to mutually support the expansion of AMP II to a second courtroom.</td>
</tr>
<tr>
<td>17. Expand enforcement capacity in key areas.</td>
<td>Implementing</td>
<td>In early 2018, the City will launch a law enforcement assisted diversion (into treatment) program in the 22nd district, with plans to evaluate and expand it in the future.</td>
</tr>
</tbody>
</table>
| 18. Provide substance use disorder assessment and treatment in the Phila Dept. of Prisons (PDP). | Implementing | Since the last report, PDP has begun showing a public service announcement on overdose recognition and naloxone use to inmates on all housing units daily, and has begun distributing naloxone to individuals at highest risk of an overdose at the time of release. Every inmate receives a prescription for naloxone with accompanying instructions. PDP has also begun enrolling in Medicaid anyone there for more than 5 days. PDP expects to begin offering Suboxone treatment to individuals with opioid use disorder by the end of December 2017. PDP continues to:  
  • Provide substance use disorder assessments of all inmates at intake, cognitive behavioral therapy for addictions and maintenance of inmates on methadone or buprenorphine.  
  • Provide withdrawal management for ~8,000 residents/year. |

Data

PDPH created an Opioid Surveillance, Epidemiology and Prevention Program that will be the central location for collecting and analyzing city-wide opioid-related data. The program is actively working with DBHIDS, the Fire Department, the Police department and community organizations, and will make regular surveillance reports available to the public. The second of these reports was released December 13, 2017. Previous quarterly reports can be found at: http://www.phila.gov/opioids
Succeeding in Recovery, thanks to Medication-Assisted Treatment (MAT)

Patrick Betteley is a Veteran of the U.S. Navy who served on two separate deployments during the Persian Gulf War. As a result of an injury he experienced during his military service, Patrick was prescribed the opioid pain reliever, Oxycodone. Patrick quickly became addicted and once Oxycodone became difficult to obtain, he turned to heroin. Patrick was active in his addiction for three years, which led him to become homeless on the streets of Kensington. During this time, Patrick was too embarrassed to be in contact with his family. Patrick recalled going to three or four detox programs, “Each time I returned to my addiction because there were no supports in place and I was still experiencing some withdrawal symptoms.”

When asked, Patrick described how he knew he was ready for treatment, “I knew I could do better. I served my country and that person on the streets wasn’t who I was.” In an effort to get connected to treatment, Patrick went to a Recovery House that provided him the phone number for Behavioral Health Special Initiative (BHSI) at the Department of Behavioral Health and Intellectual disAbility Services (DBHIDS). “The approval process was easy with BHSI.” He worked with BHSI staff to arrange placement with MAT at the Goldman Clinic. Since his prior experiences with drug-free treatment were unsuccessful, Patrick was open to trying MAT. “When you go to detox and become sober, nothing prevents you from giving in to that constant feeling of wanting to go back out and use.”

Patrick participated in MAT for two years before successfully completing his program in December 2016. He felt methadone helped control his urges to use, and the corresponding therapy provided a recovery atmosphere and social support. “Methadone was the additional support I needed until I was confident enough and ready to be in recovery completely on my own.”

When asked what he would want others to know about MAT, Patrick shared, “Methadone is temporary support until you decide you are ready, it is not necessarily lifelong assistance. Since I couldn’t hold onto the methadone myself, there was no temptation to sell it.”

Patrick will be celebrating three years of sobriety in December 2017. He has been reconnected with his family, including his two children. He is stably housed, attends to all his medical needs, and has even returned to work as an electrician.

As Patrick continues along his recovery journey, Patrick attends outpatient treatment where he formerly participated in MAT. He also accesses support through Healing Ajax, a program of Resources for Human Development (RHD), and Narcotic Anonymous groups.
ADVANCING THE SUBSTANCE USE DISORDER (SUD) TREATMENT CONTINUUM

SUD Treatment Continuum & Utilization Data

Within DBHIDS, Community Behavioral Health (CBH) manages the behavioral health services for Medicaid beneficiaries while the Division of Behavioral Health (DBH) manages care for uninsured individuals and various recovery support services.

CBH Utilization Data (1/1/16 - 12/31/16)

- 26,784 participated in SUD Treatment Services
- 84% utilized both SUD and Mental Health Treatment
- 53% were treated for an Opioid Use Disorder (OUD)

OUD was the 3rd highest cost diagnosis overall.

70% of the total costs to directly treat the primary diagnosis of SUD were for individuals with an OUD.

52% of individuals who used detoxification were recidivists to high acuity levels of care; which increases overdose risk.

David T. Jones
Commissioner
215-685-5400

DBHIDS.org/contact/resources
PHILADELPHIA
DEPARTMENT OF BEHAVIORAL HEALTH
AND INTELLECTUAL DISABILITY SERVICES

ADVANCING THE SUBSTANCE USE DISORDER (SUD)
TREATMENT CONTINUUM

DBHIDS Response to the Opioid Crisis

DBHIDS is continuing its concerted efforts to increase the availability of Medication Assisted Treatment (MAT) in all forms across all levels of care.

**MAT Expansion**
- Increased the availability of Buprenorphine from approximately 100 slots to more than 1,000 slots
- Increased availability of Buprenorphine and Naltrexone XR at Opioid Treatment Programs.

**New Levels of Care**
- Added 8 Early Intervention Programs
- Added a co-occurring Partial Hospitalization Program offering MAT

**MAT System Transformation**

DBHIDS is using detoxification to capacity and has added beds where possible. DBHIDS is employing a more comprehensive response by transforming the practice of detoxification to withdrawal management.

**Detoxification**
- Isolated level of care; Siloed programs
- Emphasizing detox as the major entry point for treatment strains the perceived availability of treatment
- Individuals who receive only detoxification are at greater risk of relapse and overdose
  Inconsistent with current evidence based practice

**Withdrawal Management**
- A medical intervention offered in every level of care, including outpatient hospital settings
- Emphasis placed on recovery initiation, MAT stabilization, and engagement in sustained treatment
- Expansion of withdrawal management in various settings will reduce perceived unavailability of treatment slots

Multiple studies have proven that Medication Assisted Treatment in combination with psychosocial treatment is effective in:

- Reducing mortality
- Lessening illicit opioid use
- Increasing retention in treatment
- Lowering criminal justice consequences of substance use
- Diminishing overall health care and societal costs

DBHIDS is linking individuals to a MAT treatment provider to align with best practice and out of concern that numerous individuals cycling through detox and residential treatment.

David T. Jones
 Commissioner
215-685-5400

DBHIDS.org/contact/resources
<table>
<thead>
<tr>
<th>Provider &amp; Contact Info</th>
<th>MAT</th>
<th>Additional Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADDICTION MEDICINE AND HEALTH ADVOCATES (AMHA) 928 MARKET ST, 19107 (215)923-4204</td>
<td>MMT induction</td>
<td>child care on site/Spanish IOP/OP</td>
</tr>
<tr>
<td>ASOCIACION PUERTORRIQUEÑOS EN MARCHA (APM) 4301 RISING SUN AVE, PHILADELPHIA, PA 19140 (267)296-7200</td>
<td>Buprenorphine induction</td>
<td>IOP/OP &amp; Spanish</td>
</tr>
<tr>
<td>BELMONT BEHAVIORAL HOSPITAL 4200 MONUMENT ROAD, 19131 (877)418-7923</td>
<td>Vivitol</td>
<td>IOP English/Spanish</td>
</tr>
<tr>
<td>CARE CLINIC- PHILA HEALTH MGMT CORP (PHMC) 1200 CALLOWHILL ST, SUITE 101, 19123 (215)825-8235</td>
<td>Buprenorphine induction</td>
<td>*Center of Excellence Health Care Center Spanish</td>
</tr>
<tr>
<td>CHANCES- PHILA HEALTH MGMT CORP (PHMC) 1200 CALLOWHILL ST, SUITE 102, 19123 (215)825-8220</td>
<td>Buprenorphine induction</td>
<td>*Center of Excellence &amp; IOP/OP females only- child care on site</td>
</tr>
<tr>
<td>COMHAR 2055 E. ALLEHENY AVE, 19134 (215)427-5800</td>
<td>Buprenorphine induction</td>
<td>OP English/Spanish</td>
</tr>
<tr>
<td>THE CONSORTIUM 451 S. UNIVERSITY AVE, 19104 (215)596.6000</td>
<td>MMT induction Vivitol</td>
<td>child care on site IOP/OP &amp; Spanish</td>
</tr>
<tr>
<td>DREXEL MEDICINE CARING TOGETHER CLINIC 4700 WISSAHICKON AVE, 19144 (215)987-2130</td>
<td>Buprenorphine/Vivitol *maintenance</td>
<td>females only/child care on site OP/English</td>
</tr>
<tr>
<td>JEVS HUMAN SERVICES - ACT I 5820 OLD YORK ROAD, 19141</td>
<td>MMT induction</td>
<td>IOP/OP English</td>
</tr>
<tr>
<td>JEVS HUMAN SERVICES - ACT II 1745 N 4TH ST, 19122 (215)230-0100</td>
<td>MMT induction</td>
<td>IOP/OP English/Spanish</td>
</tr>
<tr>
<td>JOHN F. KENNEDY BEHAVIORAL HEALTH CENTER (JFK) 907 N. BROAD ST, 19123 (215)567-2469</td>
<td>MMT induction</td>
<td>OP English</td>
</tr>
<tr>
<td>KENSINGTON HOSPITAL 136 DIAMOND ST, 19122 (215)426-8100</td>
<td>MMT induction</td>
<td>OP English</td>
</tr>
<tr>
<td>NORTH PHILA HEALTH SYSTEM - GOLDMAN CLINIC 601 W. GRAND ST, 19122 (215)787-2000</td>
<td>MMT induction</td>
<td>IOP/OP English/Spanish</td>
</tr>
<tr>
<td>NORTHEAST TREATMENT CENTERS (NET) 2701 N. BROAD ST, 19132 (215)226-1000</td>
<td>Buprenorphine induction Vivitol</td>
<td>IOP/OP English</td>
</tr>
<tr>
<td>NORTHEAST TREATMENT CENTERS (NET) 499 N. 5TH ST, 19123 (215)451-7100</td>
<td>Buprenorphine induction</td>
<td>IOP/OP English</td>
</tr>
<tr>
<td>NORTHEAST TREATMENT CENTERS (NET) 5501 CHESTNUT ST, 19139 (215)747-6480</td>
<td>Buprenorphine induction</td>
<td>IOP/OP English</td>
</tr>
<tr>
<td>NORTHEAST TREATMENT CENTERS (NET) 4625 FRANKFORD AVE, 19124 (215)451-7000</td>
<td>Buprenorphine induction</td>
<td>IOP/OP English</td>
</tr>
<tr>
<td>NORTHEAST TREATMENT CENTERS (NET) 2205 BRIDGE ST, 19137 (215)286-5490</td>
<td>Buprenorphine induction</td>
<td>IOP/OP English</td>
</tr>
<tr>
<td>NORTHEAST TREATMENT CENTERS (NET) 7520 STATE ROAD, 19136 (215)831-6024</td>
<td>Buprenorphine induction</td>
<td>IOP/OP English</td>
</tr>
<tr>
<td>NORTHWESTERN HUMAN SERVICES (NHS) PARKSIDE RECOVERY 5000 PARKSIDE AVE, 19131 (215)879-6116</td>
<td>Buprenorphine induction</td>
<td>IOP/OP English</td>
</tr>
<tr>
<td>NORTHWESTERN HUMAN SERVICES (NHS) PARKSIDE RECOVERY 5429 GERMANTOWN AVE, 19144 (215)754-0240</td>
<td>Buprenorphine induction</td>
<td>IOP/OP English</td>
</tr>
<tr>
<td>NORTHWESTERN HUMAN SERVICES (NHS) PARKSIDE RECOVERY 1182 KNOX STREET, 19154</td>
<td>Buprenorphine induction</td>
<td>IOP/OP English</td>
</tr>
<tr>
<td>PATHWAYS TO HOUSING 5201 OLD YORK ROAD, 4TH FL, SUITE 108, 19141 (215)390-6187</td>
<td>Buprenorphine induction</td>
<td>*Center of Excellence Housing Assistance</td>
</tr>
</tbody>
</table>

Intensive Outpatient Program (IOP)
Methadone Maintenance Treatment (MMT)
Outpatient Program (OP)
PHILADELPHIA
DEPARTMENT OF BEHAVIORAL HEALTH
AND INTELLECTUAL disABILITY SERVICES
IN-NETWORK ADULT COMMUNITY MEDICATION-ASSISTED TREATMENT (MAT) PROGRAMS

<table>
<thead>
<tr>
<th>Provider &amp; Contact Info</th>
<th>MAT</th>
<th>Additional Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>PATHWAYS TO RECOVERY</td>
<td>Vivitrol &amp; Buprenorphine induction MMT clinic coordination</td>
<td>*Center of Excellence Partial Hospital Program</td>
</tr>
<tr>
<td>PENN MEDICINE PRESBYTERIAN MEDICAL CENTER</td>
<td>Buprenorphine induction</td>
<td>*Center of Excellence &amp; IOP/ OP English/ Spanish</td>
</tr>
<tr>
<td>PENN MEDICINE MOTHERS MATTER PROGRAM</td>
<td>Buprenorphine induction</td>
<td>*Center of Excellence Pregnant Women</td>
</tr>
<tr>
<td>PREVENTION POINT</td>
<td>Buprenorphine induction Vivitrol</td>
<td>*Center of Excellence Harm reduction svcs &amp; English/ Spanish</td>
</tr>
<tr>
<td>PROJECT HOME</td>
<td>Buprenorphine induction Vivitrol</td>
<td>*Center of Excellence Housing Assistance</td>
</tr>
<tr>
<td>SOAR CORP</td>
<td>MMT induction</td>
<td>OP English</td>
</tr>
<tr>
<td>THOMAS JEFFERSON UNIVERSITY FAMILY CENTER</td>
<td>MMT induction</td>
<td>*Center of Excellence (MATER) &amp; English/ Spanish IOP/ OP/females only, childcare on site, pregnancy</td>
</tr>
<tr>
<td>THOMAS JEFFERSON UNIVERSITY (NARP)</td>
<td>MMT induction</td>
<td>*Center of Excellence IOP/ OP &amp; English/Spanish</td>
</tr>
<tr>
<td>TEMPLE TWO Program</td>
<td>Buprenorphine induction</td>
<td>*Center of Excellence Partners with the Wedge MC &amp; OB-Gyn Svcs</td>
</tr>
<tr>
<td>WEDGE MEDICAL CENTER</td>
<td>Buprenorphine induction Vivitrol</td>
<td>*Partners with Temple &amp; English/ Spanish TWO Center of Excellence &amp; IOP/ OP</td>
</tr>
<tr>
<td>WEDGE MEDICAL CENTER</td>
<td>Buprenorphine induction Vivitrol</td>
<td>IOP/ OP English</td>
</tr>
<tr>
<td>WEDGE MEDICAL CENTER</td>
<td>Buprenorphine induction Vivitrol</td>
<td>IOP/ OP English</td>
</tr>
</tbody>
</table>

Intensive Outpatient Program (IOP)
Methadone Maintenance Treatment (MMT)
Outpatient Program (OP)